| Literature DB >> 16797735 |
Christophe Mathé1, Gilles Gosselin.
Abstract
The discovery that some nucleoside analogues endowed with the unnatural L-configuration can possess biological activities has been a significant breakthrough in antiviral chemotherapy. In this regard, lamivudine (3TC) was the first L-nucleoside enantiomer approved against HIV and HBV, and several other L-nucleosides are currently under clinical development as antiviral agents.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16797735 DOI: 10.1016/j.antiviral.2006.04.017
Source DB: PubMed Journal: Antiviral Res ISSN: 0166-3542 Impact factor: 5.970